445 related articles for article (PubMed ID: 35987605)
1. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
[TBL] [Abstract][Full Text] [Related]
2. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco.
Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R
PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Sinopharm's BBIBP-CorV Booster Vaccination against COVID-19-Related Severe and Critical Cases and Deaths in Morocco during the Omicron Wave.
Belayachi J; Mhayi A; Majidi H; El Fahime E; Abouqal R
Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543878
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
[TBL] [Abstract][Full Text] [Related]
7. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE).
Ismail AlHosani F; Eduardo Stanciole A; Aden B; Timoshkin A; Najim O; Abbas Zaher W; AlSayedsaleh AlDhaheri F; Al Mazrouie S; Rizvi TA; Mustafa F
Vaccine; 2022 Mar; 40(13):2003-2010. PubMed ID: 35193793
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
[TBL] [Abstract][Full Text] [Related]
9. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
[TBL] [Abstract][Full Text] [Related]
10. Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel.
Park S; Gatchalian KK; Oh H
Cureus; 2022 Jul; 14(7):e27323. PubMed ID: 36043010
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan.
Nadeem I; Ul Munamm SA; Ur Rasool M; Fatimah M; Abu Bakar M; Rana ZK; Khatana UF; Jordon L; Saqlain M; Mahdi N; McLoughlin H
Postgrad Med J; 2023 Jun; 99(1171):463-469. PubMed ID: 37294716
[TBL] [Abstract][Full Text] [Related]
12. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
[TBL] [Abstract][Full Text] [Related]
15. Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S; Wiangcharoen R; Nanthapisal S; Kamolratakul S; Lawpoolsri S; Jongkaewwattana A; Thitithanyanont A; Luvira V; Chinwangso P; Thanthamnu N; Chantratita N; Lim JK; Anh Wartel T; Excler JL; Ryser MF; Leong C; Mak TK; Pitisuttithum P
Vaccine; 2023 Jul; 41(32):4648-4657. PubMed ID: 37344265
[TBL] [Abstract][Full Text] [Related]
16. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X
Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349
[TBL] [Abstract][Full Text] [Related]
18. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.
Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V
JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
Moghnieh R; Mekdashi R; El-Hassan S; Abdallah D; Jisr T; Bader M; Jizi I; Sayegh MH; Rahman Bizri A
Vaccine; 2021 Nov; 39(46):6713-6719. PubMed ID: 34656379
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
Erfanpoor S; Banihashemi SR; Mokhbaeralsafa L; Kalantari S; Es-Haghi A; Nofeli M; Rezaei Mokarram A; Sadeghi F; Hajimoradi M; Razaz SH; Taghdiri M; Lotfi M; Khorasani A; Ansarifar A; Masoumi S; Mohazzab A; Filsoof S; Mohseni V; Shahsavan M; Gharavi N; Setarehdan SA; Rabiee MH; Fallah Mehrabadi MH; Solaymani-Dodaran M
BMC Med; 2024 Feb; 22(1):78. PubMed ID: 38378570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
